Health Products

Centre for Probe Development and Commercialization Products Recall (2019-04-17)

· Published by Health Canada · Official notice

Details

Alert type: Drug Recall
Category: Drugs
Issue: Product Safety
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type III

Summary

Product

A. Glucovision (Phosphate) 540 GBQ / Vial solution

Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Products

Lot or serial numberCompaniesBrand nameDosage formDIN, NPN, DIN-HIMStrength
T-190417FDG-1
Recalling Firm
Centre for Probe Development and Commercialization (CPDC)
1280 Main St. W. NRB-A316
Hamilton
L8S 4K1
Ontario
CANADA
Marketing Authorization Holder
Centre for Probe Development and Commercialization (CPDC)
1280 Main St. W. NRB-A316
Hamilton
L8S 4K1
Ontario
CANADA
B. Glucovision (Citrate) 453 GBQ / Vial solutionSolutionDIN 02328771Fludeoxyglucose 18F 453 GBQ/vial
T-190417FDG-2
Recalling Firm
Centre for Probe Development and Commercialization (CPDC)
1280 Main St. W. NRB-A316
Hamilton
L8S 4K1
Ontario
CANADA
Marketing Authorization Holder
Centre for Probe Development and Commercialization (CPDC)
1280 Main St. W. NRB-A316
Hamilton
L8S 4K1
Ontario
CANADA
A. Glucovision (Phosphate) 540 GBQ / Vial solutionSolutionDIN 02486652Fludeoxyglucose 18F 540 GBQ/vial

Introduction

A. Glucovision (Phosphate) 540 GBQ / Vial solution

B. Glucovision (Citrate) 453 GBQ / Vial solution

Reason

Affected lots may contain particulate matter.

Depth of distribution

Healthcare establishments, End users
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime